德国、法国和英国经典型霍奇金淋巴瘤患者与医生对一线治疗方案的偏好
该横断面在线离散选择实验调查了德国、法国和英国的381例霍奇金淋巴瘤患者和357名血液科/肿瘤科医生,评估其对ABVD、BEACOPPescalated和BV-AVD方案相关属性的偏好。患者最重视5年无进展生存和总生存,而医生对各属性的相对重要性随所推荐的假设患者描述不同而变化。
要点
- 患者最重视5年无进展生存和总生存这两个治疗属性。
- 医生对各属性的偏好权重随假设患者描述不同而变化。
- 考虑无生育意愿的年轻女性或年轻男性时,PFS和OS对医生推荐影响最强。
核心结论
- 5年无进展生存和总生存是患者最重要的治疗属性,而医生对各属性的相对重要性和各水平的偏好权重随所推荐的假设患者描述不同而变化。
研究设计与样本
- 横断面在线离散选择实验,纳入德国、法国和英国的霍奇金淋巴瘤患者(n=381)和血液科/肿瘤科医生(n=357)。
主要发现
- 患者最重视5年无进展生存和总生存。
- 医生对各属性的相对重要性和各水平偏好权重随假设患者描述不同而变化。
- 考虑无生育意愿的年轻女性或年轻男性时,PFS和OS对医生推荐影响最强。
- 考虑生育意愿未知的年轻女性时,不孕不育对医生治疗决策比PFS更重要。
- 考虑老年患者时,不良事件导致的住院在治疗决策中作用最大。
关键数值与推荐
- 评估属性包括无进展生存、总生存以及神经病变、肺损伤、不孕不育和不良事件导致住院的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
First-line treatments for classical Hodgkin lymphoma (HL) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPPescalated (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). To further improve overall outcomes, positron emission tomography-driven strategies and ABVD or BEACOPP variants incorporating the antibody-drug conjugate brentuximab vedotin (BV) or anti-PD1 antibodies are under investigation in advanced-stage patients. The present study aimed to elicit preferences for attributes associated with ABVD, BEACOPPescalated and BV-AVD (BV, adriamycin, vinblastine and dacarbazine) among patients and physicians. Cross-sectional online discrete choice experiments were administered to HL patients (n = 381) and haematologists/oncologists (n = 357) in France, Germany and the United Kingdom. Included attributes were progression-free survival (PFS), overall survival (OS), and the risk of neuropathy, lung damage, infertility and hospitalisation due to adverse events. Whereas 5-year PFS and OS were the most important treatment attributes to patients, the relative importance of each attribute and preference weights for each level varied among physicians according to the description of the hypothetical patient for whom treatment was recommended. PFS and OS most strongly influenced physicians' recommendations when considering young female patients who did not want children or young male patients. Infertility was more important to physicians' treatment decision than PFS when considering young women with unknown fertility preferences, whereas hospitalisations due to adverse events played the largest role in treatment decisions for older patients.
引用
- Bröckelmann PJ, McMullen S, Wilson JB, et al. Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. Br J Haematol. 2018. PMID: 30239982. doi:10.1111/bjh.15566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。